Skip to main content

Advertisement

Table 4 Comparison of the percentages of B cell subsets between untreated MS patients, IFN-β-treated MS patients, and healthy controls

From: Long-term use of interferon-β in multiple sclerosis increases Vδ1Vδ2Vγ9 γδ T cells that are associated with a better outcome

  Untreated MS (n = 35) MS w/ IFN-β (n = 21) HCs (n = 44) p value (K-W test) padj value
Untreated MS vs. HCs MS w/ IFN-β vs. HCs Untreated MS vs. MS w/ IFN-β
Naïve (CD27IgD+) 46.3 (27.9–56.8) 48.9 (37.7–58.9) 51.8 (41.4–60.6) NS
Memory (CD27+) 14.8 (10.3–27.0) 9.84 (6.89–15.2) 22.7 (16.9–29.9) < 0.001 NS < 0.001 0.009
 CS+ memory (CD27+IgD) 12.4 (9.27–24.8) 7.97 (6.10–14.0) 18.8 (14.4–25.2) < 0.001 NS < 0.001 0.006
 CS memory (CD27+IgD+) 1.91 (0.83–2.68) 0.99 (0.85–1.67) 3.49 (2.49–4.67) < 0.001 NS (0.058) < 0.001 NS
Plasmablasts (CD38highCD20) 0.31 (0.14–0.65) 0.32 (0.25–0.53) 0.37 (0.24–0.67) NS
Transitional (CD24highCD38high) 3.16 (1.75–5.93) 5.90 (1.92–7.66) 3.14 (2.32–4.45) NS
  1. Values are the median (IQR). Percentages of each population in total B cells are shown
  2. p values (K-W test) were obtained by Kruskal-Wallis analyses, and if they were statistically significant, then padj values were calculated using multivariate linear regression analyses adjusted for age and sex
  3. CS+ class-switched, CS non-class-switched, HCs healthy controls, IFN-β interferon-β, IQR interquartile ranges, K-W Kruskal-Wallis, MS multiple sclerosis, NS not significant, w/ with